A multidisciplinary team at the University of Cape Town (UCT) is poised to make significant advancements in cancer treatment ...

Red light therapy devices and treatments are trending. Madeleine Spencer explains its myriad benefits and recommends the best ...

Just a short distance outside of Fort Collins on the Colorado State University Foothills Campus sits one of the most powerful ...

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Work is set to begin next week on the 144th Avenue overpass in Dorr Township, local authorities say. According to the ...

Small companies attempting to help solve a global crisis in drug-resistant infections with novel treatments are facing a wall ...

Traffic disruptions and lane reductions are set to begin on northbound I-495 (Capital Beltway Inner Loop) near Tysons, ...

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.

Subscribe today to gain access to every Research Intelligencer article we publish as well as the exclusive daily newsletter, full access to The MediaPost Cases, first-look research and daily insights ...

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Alzamend Neuro, Inc. (ALZN) is a stock that can certainly grab ...